Election committee for Vitrolife AB (publ)

        Print
| Source: Vitrolife AB
The following people have been appointed as members of Vitrolife’s election
committee for the Annual General Meeting in 2013:
Henrik Blomquist, representing Bure Equity AB
Johan Ståhl, representing Lannebo Fonder
Martin Lewin, representing Eccenovo AB and Thomas Olausson
Patrik Tigerschiöld, Chairman of the Board

The appointments have been made in accordance with the instructions regarding
principles for the appointment of the company election committee which were
determined at the Annual General Meeting of Vitrolife on April 19, 2012.

The Annual General Meeting of Vitrolife AB (publ) will be held on April 29, 2013
in Gothenburg.
Shareholders who wish to have an item considered at the Annual General Meeting
can submit a request to the Board to this effect. Such a request for an item to
be considered is to be sent to Vitrolife AB (publ), Att: Chairman of the Board,
Box 9080, 400 92 Gothenburg, and must have been received by the Board no later
than seven weeks before the Annual General Meeting, or otherwise in such good
time that the matter, where necessary, can be included in the notice to attend
the Annual General Meeting.

Gothenburg, October 15, 2012

VITROLIFE AB (publ)
Queries should be addressed to:

Patrik Tigerschiöld, Chairman of the Board, phone 46 8 614 00 20
Mikael Engblom, CFO, phone 46 31 721 80 14

Vitrolife is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on
October 15, at 4.00 p.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
Vitrolife (http://www.vitrolife.com/en/Corporate/) is a global
biotechnology/medical device Group. The
Fertility (http://www.vitrolife.com/en/Fertility/) product area works with
nutrient solutions (media), cryopreservation products and advanced consumable
instruments such as needles and pipettes, for the treatment of human
infertility. Work is also carried out to enable the use and handling of stem
cells for therapeutic purposes.

Vitrolife (http://www.vitrolife.com/en/Corporate/) today has approximately 220
employees and its products are sold in almost 90 markets. The company is
headquartered in Gothenburg, Sweden, and there are also offices in USA,
Australia, France, Italy, United Kingdom, China and Japan. The Vitrolife
share (http://www.vitrolife.com/en/Corporate/Financial/The-share1/) is listed on
NASDAQ OMX
Stockholm (http://www.nasdaqomxnordic.com/aktier/shareinformation?Instrument=SSE
1 
3469), Small Cap.

________________________________________________________________________________
_ 
________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail:
info@vitrolife.com. Website: www.vitrolife.com/